These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 18369019)

  • 21. Pre-emptive treatment of CMV DNAemia in paediatric stem cell transplantation: the impact of recipient and donor CMV serostatus on the incidence of CMV disease and CMV-related mortality.
    Matthes-Martin S; Lion T; Aberle SW; Fritsch G; Lawitschka A; Bittner B; Frommlet F; Gadner H; Peters C
    Bone Marrow Transplant; 2003 May; 31(9):803-8. PubMed ID: 12732888
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytomegalovirus viremia, viruria and disease after autologous peripheral blood stem cell transplantation: no need for surveillance.
    Bilgrami S; Aslanzadeh J; Feingold JM; Bona RD; Clive J; Dorsky D; Edwards RL; Tutschka PJ
    Bone Marrow Transplant; 1999 Jul; 24(1):69-73. PubMed ID: 10435738
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HLA-DRB1*09 is associated with increased incidence of cytomegalovirus infection and disease after allogeneic hematopoietic stem cell transplantation.
    Du J; Liu J; Gu J; Zhu P
    Biol Blood Marrow Transplant; 2007 Dec; 13(12):1417-21. PubMed ID: 18022570
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cytomegalovirus (CMV) infections in children undergoing hematopoetic stem cell transplantation.
    Zaucha-Prazmo A; Wójcik B; Drabko K; Choma M; Kowalczyk JR
    Pediatr Hematol Oncol; 2005 Jun; 22(4):271-6. PubMed ID: 16020113
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CMV pneumonia in allogeneic BMT recipients undergoing early treatment of pre-emptive ganciclovir therapy.
    Machado CM; Dulley FL; Boas LS; Castelli JB; Macedo MC; Silva RL; Pallota R; Saboya RS; Pannuti CS
    Bone Marrow Transplant; 2000 Aug; 26(4):413-7. PubMed ID: 10982288
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rituximab therapy increased post-transplant cytomegalovirus complications in Non-Hodgkin's lymphoma patients receiving autologous hematopoietic stem cell transplantation.
    Lee MY; Chiou TJ; Hsiao LT; Yang MH; Lin PC; Poh SB; Yen CC; Liu JH; Teng HW; Chao TC; Wang WS; Chen PM
    Ann Hematol; 2008 Apr; 87(4):285-9. PubMed ID: 17943285
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The value of immunoprophylaxis for cytomegalovirus infection with intravenous immunoglobulin in pediatric liver transplant recipients receiving a low-dose immunosupressive regimen.
    Krampe K; Briem-Richter A; Fischer L; Nashan B; Ganschow R
    Pediatr Transplant; 2010 Feb; 14(1):67-71. PubMed ID: 19175517
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term renal graft function and survival in patients with high-risk for cytomegalovirus infection receiving preemptive therapy.
    Alberú J; Morales-Buenrostro LE; Correa-Rotter R; Muñoz-Trejo T; Zúñiga-Varga J; Cuéllar-González JV; Mayorga-Madrigal H; Vanegas-Carrero R; Aranda F; Rodríguez-Romo R; Herrera-Garcia C; González-Michaca L; Sierra-Madero JG
    Rev Invest Clin; 2008; 60(5):365-74. PubMed ID: 19227433
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Once daily ganciclovir as initial pre-emptive therapy delayed until threshold CMV load > or =10000 copies/ml: a safe and effective strategy for allogeneic stem cell transplant patients.
    Verkruyse LA; Storch GA; Devine SM; Dipersio JF; Vij R
    Bone Marrow Transplant; 2006 Jan; 37(1):51-6. PubMed ID: 16284613
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Surveillance of cytomegalovirus infection in haematopoietic stem cell transplantation patients.
    Bonon SH; Menoni SM; Rossi CL; De Souza CA; Vigorito AC; Costa DB; Costa SC
    J Infect; 2005 Feb; 50(2):130-7. PubMed ID: 15667914
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cytomegalovirus infection after autologous stem cell transplantation: incidence and outcome in a group of patients undergoing a surveillance program.
    Rossini F; Terruzzi E; Cammarota S; Morini F; Fumagalli M; Verga L; Elli E; Verga M; Miccolis I; Parma M; Pogliani EM
    Transpl Infect Dis; 2005; 7(3-4):122-5. PubMed ID: 16390400
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cytomegalovirus prophylaxis with intravenous polyvalent immunoglobulin in high-risk renal transplant recipients.
    Leroy F; Sechet A; Abou Ayache R; Thierry A; Belmouaz S; Desport E; Bauwens M; Bridoux F; Touchard G
    Transplant Proc; 2006 Sep; 38(7):2324-6. PubMed ID: 16980080
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High-grade cytomegalovirus antigenemia after hematopoietic stem cell transplantation.
    Asano-Mori Y; Oshima K; Sakata-Yanagimoto M; Nakagawa M; Kandabashi K; Izutsu K; Hangaishi A; Motokura T; Chiba S; Kurokawa M; Hirai H; Kanda Y
    Bone Marrow Transplant; 2005 Nov; 36(9):813-9. PubMed ID: 16151428
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rising antigenemia levels may be misleading in pre-emptive therapy of human cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients.
    Gerna G; Lilleri D; Zecca M; Alessandrino EP; Baldanti F; Revello MG; Locatelli F
    Haematologica; 2005 Apr; 90(4):526-33. PubMed ID: 15820949
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bedside leukoreduction of cellular blood components in preventing cytomegalovirus transmission in allogeneic bone marrow transplant recipients: a retrospective study.
    Narvios AB; Lichtiger B
    Haematologica; 2001 Jul; 86(7):749-52. PubMed ID: 11454531
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cytomegalovirus infection after allogeneic transplantation: comparison of cord blood with peripheral blood and marrow graft sources.
    Walker CM; van Burik JA; De For TE; Weisdorf DJ
    Biol Blood Marrow Transplant; 2007 Sep; 13(9):1106-15. PubMed ID: 17697973
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-dose acyclovir and pre-emptive ganciclovir to prevent cytomegalovirus disease in myeloablative and non-myeloablative allogeneic stem cell transplantation.
    Nakamura R; Cortez K; Solomon S; Battiwalla M; Gill VJ; Hensel N; Childs R; Barrett AJ
    Bone Marrow Transplant; 2002 Aug; 30(4):235-42. PubMed ID: 12203140
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interferon gamma 13-CA-repeat homozygous genotype and a low proportion of CD4(+) lymphocytes are independent risk factors for cytomegalovirus reactivation with a high number of copies in hematopoietic stem cell transplantation recipients.
    Jaskula E; Dlubek D; Duda D; Bogunia-Kubik K; Mlynarczewska A; Lange A
    Biol Blood Marrow Transplant; 2009 Oct; 15(10):1296-305. PubMed ID: 19747638
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cytomegalovirus shedding in the oral cavity of allogeneic haematopoietic stem cell transplant patients.
    Correia-Silva Jde F; Victória JM; Guimarães AL; Salomão UE; de Abreu MH; Bittencourt H; Gomez RS
    Oral Dis; 2007 Mar; 13(2):163-9. PubMed ID: 17305617
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cytomegalovirus infection in pediatric allogenic hematopoietic stem cell transplantation. A single center experience.
    Sedky M; Mekki Y; Mialou V; Bleyzac N; Girard S; Salama E; Abdel Rahman H; Bertrand Y
    Pediatr Hematol Oncol; 2014 Nov; 31(8):743-53. PubMed ID: 24308761
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.